Avastin (Intravitreal Bevacizumab) (Genentech Inc.) for treatment of choroidal neovascularization secondary to pathological myopia

Record ID 32010000969
English
Authors' objectives:

Pathological myopia refers to an abnormal elongation of the eye and is associated with extreme nearsightedness. It can result in a progressive, severe loss of vision and is requently related to the development of choroidal neovascularization (CNV). Pathological myopia has an incidence of approximately 2% in the general U.S. population and is the seventh leading cause of legal blindness. It occurs most often in those of Chinese, Japanese, Middle Eastern, or Jewish descent; and it is more common in women than men. Pathological myopia is the primary cause of CNV in individuals younger than 50 years of age. Nearly 10% of eyes with pathological myopia develop CNV. If left untreated, the visual prognosis of CNV secondary to pathological myopia is poor, and a high proportion of patients develop rapid and potentially irreversible vision loss.

Details
Project Status: Completed
URL for project: http://www.hayesinc.com
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Injections
  • Antibodies, Monoclonal
  • Choroidal Neovascularization
  • Myopia, Degenerative
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: 2010 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.